Novel 4-substituted 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents

A compound of Formula (I),

• a tautomer or a stereoisomeric form thereof, wherein
• Het is a heterocycle having formula (a)
• R1a is Br or Cl;
• R2a is —(CR8aR9a)n—R10a;
• each R8a and R9a are independently chosen from the group consisting of H, C1-C10alkyl and C3-C7cycloalkyl;
• or R8a and R9a taken together form a 4 to 6 membered aliphatic ring;
• wherein the 4 to 6 membered aliphatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;
• R10a is selected from the group consisting of H, C1-C6alkyl, R11, OH, CF3, CHF2, F, Cl, SO2CH3, SO2C3-C7cycloalkyl, NR8aSO2R8a, SO2NR8aR9a, NR8aSO2C3-C7cycloalkyl, CN, NR8aR9a, COOH, COOR8a, CONR8aR9a, OCOC1-C6alkyl, CONR8aSO2R9a, CONR8aSO2NR8aR9a, a 4 to 6 membered aliphatic ring and a 5 to 6 membered aromatic ring;
• wherein the aliphatic or aromatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;
• R11 is selected from the group consisting of C1-C6 alkyl, C3-C7cycloalkyl, phenyl, pyridinyl and pyrazolyl;
• each substituted with one or more substituents each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen;
• n is an integer having a value from 1 to 6;
• R5 is selected from the group consisting of C1-C6alkyl, C1-C6alkyloxy, CN, CF3 and halo;
• R4 is selected from the group consisting of hydrogen, tert-butyl, C3-C7cycloalkyl, CH(CH3)(CF3), C2-C10alkenyl, CH2CF3, SO2CH3, —CH2-p-fluorophenyl, aryl, Het1, Het2 and C3-C7cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C1-C4alkyl;
• aryl represents phenyl or naphthalenyl;
• said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C1-C4alkyloxy, OH, CN, CF2H, CF3, CONR8aR9a, COOR8a, CON(R8a)SO2R9a, CON(R8a)SO2N(R8aR9a), NR8aR9a, NR8aCOOR9a, OCOR8a, NR8aSO2R9a, SO2NR8aR9a, SO2R8a, OCONR8aR9a, OCONR8aR11a, N(R8a)CON(R8aR9a), N(R8a)COOR11a, and C1-C4alkyl;
• Het1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N;
• or a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N;
• said Het1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C1-C4alkyloxy, SO2R8a, C1-C4alkylcarbonyl, C1-C4alkyloxycarbonyl, CO(aryl), COHet2, pyridinyl, CF3, SO2N(C1-C4alkyl)2, SO2NH(C1-C4alkyl), NH(C═O)(C1-4alkyl), (C═O)NH(C1-4alkyl), (C═S)NH(C1-4alkyl), C1-C4alkyl and C1-C4alkyl substituted with one hydroxy;
• Het2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N;
• or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N;
• said Het2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C1-C4alkyloxy, OH, CN, CF2H, CF3, CONR8aR9a, COOR8a, CON(R8a)SO2R9a, CON(R8a)SO2N(R8aR9a), NR8aR9a, NR8aCOOR9a, OCOR8a, NR8aSO2R9a, SO2NR8aR9a, SO2R8a, OCONR8aR9a, OCONR8aR11a, N(R8a)CON(R8aR9a), N(R8a)COOR11a and C1-C4alkyl;
• R11a is selected from the group consisting of phenyl, pyridinyl and pyrazolyl;
• each optionally substituted with one or more substituents each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen;
• or R11a is C1-C6 alkyl or C3-C7cycloalkyl;
• each substituted with one or more substituents each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen;
• Z is CH or N;
• or a pharmaceutically acceptable addition salt or a solvate thereof.